Reimagining Medicine

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials Expected currency impact for full year 2023 Currency impact vs. PY %pts, assuming mid-July exchange rates prevail in 2023 FX impact on Net sales References Abbreviations FX impact on Core operating income I FINANCIAL PROFILE 3 2 0 to -1 -1 -3 -2 to -3 -6 -5 -5 -8 -7 -8 I FY Q1 Q2 Q3 Q4 FY FY Q1 Q2 Q3 Q4 FY 2022 2023 2022 2023 Actual Simulation 40 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation